AG
LXEO icon

Artal Group’s Lexeo Therapeutics LXEO Stock Holding History

Artal Group’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-603,435
Closed -$9.68M – 55
2024
Q2 		$9.68M Sell
603,435
-198,281
-25% -$2.88M 0.25% 41
2024
Q1 		$12.6M Buy
801,716
+198,281
+33% +$3.1M 0.32% 38
2023
Q4 		$8.1M Buy
+603,435
New +$7.5M 0.27% 38

Other funds holding LXEO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DCP
D1 Capital Partners New York $11.2B AUM 15.78% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Artal Group's LXEO Position: Q3 2024 in Review

Artal Group sold out of Lexeo Therapeutics (LXEO) in Q3 2024, closing a stake of 603,435 shares — an estimated $9.68M sold.

Artal Group first reported a position in LXEO in Q4 2023 and held it in 3 quarters. The position peaked at $12.6M in Q1 2024. 69 funds tracked by Wall St. Rank hold LXEO as of Q3 2024.

  • Artal Group reported no remaining Lexeo Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Artal Group sold 603,435 Lexeo Therapeutics shares in Q3 2024, an estimated $9.68M.
  • Artal Group first reported a position in Lexeo Therapeutics in Q4 2023 and held it in 3 quarters.
  • Artal Group's Lexeo Therapeutics position peaked at $12.6M in Q1 2024.
  • 69 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.